Sascha Weggen, Dr. rer. nat. - Publications

Neuropathology University of Duesseldof 

80 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Walter S, Jumpertz T, Hüttenrauch M, Ogorek I, Gerber H, Storck SE, Zampar S, Dimitrov M, Lehmann S, Lepka K, Berndt C, Wiltfang J, Becker-Pauly C, Beher D, Pietrzik CU, ... ... Weggen S, et al. The metalloprotease ADAMTS4 generates N-truncated Aβ4-x species and marks oligodendrocytes as a source of amyloidogenic peptides in Alzheimer's disease. Acta Neuropathologica. PMID 30426203 DOI: 10.1007/s00401-018-1929-5  0.6
2018 Hüttenrauch M, Ogorek I, Klafki H, Otto M, Stadelmann C, Weggen S, Wiltfang J, Wirths O. Glycoprotein NMB: a novel Alzheimer's disease associated marker expressed in a subset of activated microglia. Acta Neuropathologica Communications. 6: 108. PMID 30340518 DOI: 10.1186/s40478-018-0612-3  0.44
2018 Storck SE, Hartz AMS, Bernard J, Wolf A, Kachlmeier A, Mahringer A, Weggen S, Pahnke J, Pietrzik CU. The concerted amyloid-beta clearance of LRP1 and ABCB1/P-gp across the blood-brain barrier is linked by PICALM. Brain, Behavior, and Immunity. PMID 30041013 DOI: 10.1016/j.bbi.2018.07.017  0.6
2018 Lesuis SL, Weggen S, Baches S, Lucassen PJ, Krugers HJ. Targeting glucocorticoid receptors prevents the effects of early life stress on amyloid pathology and cognitive performance in APP/PS1 mice. Translational Psychiatry. 8: 53. PMID 29491368 DOI: 10.1038/s41398-018-0101-2  0.6
2018 Goel P, Jumpertz T, Tichá A, Ogorek I, Mikles DC, Hubalek M, Pietrzik CU, Strisovsky K, Schmidt B, Weggen S. Discovery and validation of 2-styryl substituted benzoxazin-4-ones as a novel scaffold for rhomboid protease inhibitors. Bioorganic & Medicinal Chemistry Letters. PMID 29463448 DOI: 10.1016/j.bmcl.2018.02.017  0.6
2017 Goel P, Jumpertz T, Mikles DC, Tichá A, Nguyen MTN, Verhelst S, Hubalek M, Johnson DC, Bachovchin DA, Ogorek I, Pietrzik CU, Strisovsky K, Schmidt B, Weggen S. Discovery and Biological Evaluation of Potent and Selective N-Methylene Saccharin-Derived Inhibitors for Rhomboid Intramembrane Proteases. Biochemistry. PMID 29185711 DOI: 10.1021/acs.biochem.7b01066  0.6
2017 Wirths O, Walter S, Kraus I, Klafki HW, Stazi M, Oberstein TJ, Ghiso J, Wiltfang J, Bayer TA, Weggen S. N-truncated Aβ4-x peptides in sporadic Alzheimer's disease cases and transgenic Alzheimer mouse models. Alzheimer's Research & Therapy. 9: 80. PMID 28978359 DOI: 10.1186/s13195-017-0309-z  0.44
2017 Bradshaw NJ, Trossbach SV, Köber S, Walter S, Prikulis I, Weggen S, Korth C. Disrupted in Schizophrenia 1 regulates the processing of reelin in the perinatal cortex. Schizophrenia Research. PMID 28433501 DOI: 10.1016/j.schres.2017.04.012  0.36
2016 Schönherr C, Bien J, Isbert S, Wichert R, Prox J, Altmeppen H, Kumar S, Walter J, Lichtenthaler SF, Weggen S, Glatzel M, Becker-Pauly C, Pietrzik CU. Generation of aggregation prone N-terminally truncated amyloid β peptides by meprin β depends on the sequence specificity at the cleavage site. Molecular Neurodegeneration. 11: 19. PMID 26895626 DOI: 10.1186/s13024-016-0084-5  1
2015 Antonios G, Borgers H, Richard BC, Brauß A, Meißner J, Weggen S, Pena V, Pillot T, Davies SL, Bakrania P, Matthews D, Brownlees J, Bouter Y, Bayer TA. Alzheimer therapy with an antibody against N-terminal Abeta 4-X and pyroglutamate Abeta 3-X. Scientific Reports. 5: 17338. PMID 26626428 DOI: 10.1038/srep17338  1
2015 Storck SE, Meister S, Nahrath J, Meißner JN, Schubert N, Di Spiezio A, Baches S, Vandenbroucke RE, Bouter Y, Prikulis I, Korth C, Weggen S, Heimann A, Schwaninger M, Bayer TA, et al. Endothelial LRP1 transports amyloid-β1-42 across the blood-brain barrier. The Journal of Clinical Investigation. PMID 26619118 DOI: 10.1172/JCI81108  1
2015 Rabiej VK, Pflanzner T, Wagner T, Götze K, Storck S, Eble JA, Weggen S, Mueller-Klieser W, Pietrzik CU. Low density lipoprotein receptor-related protein 1 mediated endocytosis of β1-integrin influences cell adhesion and cell migration. Experimental Cell Research. PMID 26610862 DOI: 10.1016/j.yexcr.2015.11.020  1
2015 Meister S, Storck SE, Hameister E, Behl C, Weggen S, Clement AM, Pietrzik CU. Expression of the ALS-causing variant hSOD1(G93A) leads to an impaired integrity and altered regulation of claudin-5 expression in an in vitro blood-spinal cord barrier model. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 35: 1112-21. PMID 25853911 DOI: 10.1038/jcbfm.2015.57  1
2015 Richard BC, Kurdakova A, Baches S, Bayer TA, Weggen S, Wirths O. Gene Dosage Dependent Aggravation of the Neurological Phenotype in the 5XFAD Mouse Model of Alzheimer's Disease. Journal of Alzheimer's Disease : Jad. 45: 1223-36. PMID 25697701 DOI: 10.3233/JAD-143120  1
2015 Flesch D, Ness J, Lamers C, Dehm F, Popella S, Steri R, Ogorek I, Hieke M, Dannhardt G, Werz O, Weggen S, Schubert-Zsilavecz M. SAR-studies of γ-secretase modulators with PPARγ-agonistic and 5-lipoxygenase-inhibitory activity for Alzheimer's disease. Bioorganic & Medicinal Chemistry Letters. 25: 841-6. PMID 25575659 DOI: 10.1016/j.bmcl.2014.12.073  1
2015 Hüttenrauch M, Baches S, Gerth J, Bayer TA, Weggen S, Wirths O. Neprilysin deficiency alters the neuropathological and behavioral phenotype in the 5XFAD mouse model of Alzheimer's disease. Journal of Alzheimer's Disease : Jad. 44: 1291-302. PMID 25408216 DOI: 10.3233/JAD-142463  1
2014 Gowert NS, Donner L, Chatterjee M, Eisele YS, Towhid ST, Münzer P, Walker B, Ogorek I, Borst O, Grandoch M, Schaller M, Fischer JW, Gawaz M, Weggen S, Lang F, et al. Blood platelets in the progression of Alzheimer's disease. Plos One. 9: e90523. PMID 24587388 DOI: 10.1371/journal.pone.0090523  1
2013 Meister S, Zlatev I, Stab J, Docter D, Baches S, Stauber RH, Deutsch M, Schmidt R, Ropele S, Windisch M, Langer K, Wagner S, von Briesen H, Weggen S, Pietrzik CU. Nanoparticulate flurbiprofen reduces amyloid-β42 generation in an in vitro blood-brain barrier model. Alzheimer's Research & Therapy. 5: 51. PMID 24280275 DOI: 10.1186/alzrt225  1
2013 Maier W, Bednorz M, Meister S, Roebroek A, Weggen S, Schmitt U, Pietrzik CU. LRP1 is critical for the surface distribution and internalization of the NR2B NMDA receptor subtype. Molecular Neurodegeneration. 8: 25. PMID 23866919 DOI: 10.1186/1750-1326-8-25  1
2013 Naumann EC, Göring S, Ogorek I, Weggen S, Schmidt B. Membrane anchoring γ-secretase modulators with terpene-derived moieties. Bioorganic & Medicinal Chemistry Letters. 23: 3852-6. PMID 23707256 DOI: 10.1016/j.bmcl.2013.04.070  1
2013 Wagner T, Dieckmann M, Jaeger S, Weggen S, Pietrzik CU. Stx5 is a novel interactor of VLDL-R to affect its intracellular trafficking and processing. Experimental Cell Research. 319: 1956-72. PMID 23701949 DOI: 10.1016/j.yexcr.2013.05.010  1
2012 Rennhack A, Jumpertz T, Ness J, Baches S, Pietrzik CU, Weggen S, Bulic B. Synthesis of a potent photoreactive acidic γ-secretase modulator for target identification in cells. Bioorganic & Medicinal Chemistry. 20: 6523-32. PMID 23000293 DOI: 10.1016/j.bmc.2012.08.034  1
2012 Bien J, Jefferson T, Causević M, Jumpertz T, Munter L, Multhaup G, Weggen S, Becker-Pauly C, Pietrzik CU. The metalloprotease meprin β generates amino terminal-truncated amyloid β peptide species. The Journal of Biological Chemistry. 287: 33304-13. PMID 22879596 DOI: 10.1074/jbc.M112.395608  1
2012 Zettl H, Ness J, Hähnke V, Beher D, Jumpertz T, Saric A, Baumann K, Pietrzik CU, Bulic B, Schneider G, Weggen S. Discovery of γ-secretase modulators with a novel activity profile by text-based virtual screening. Acs Chemical Biology. 7: 1488-95. PMID 22725102 DOI: 10.1021/cb3001952  1
2012 Weggen S, Beher D. Molecular consequences of amyloid precursor protein and presenilin mutations causing autosomal-dominant Alzheimer's disease. Alzheimer's Research & Therapy. 4: 9. PMID 22494386 DOI: 10.1186/alzrt107  1
2012 Hartenfeller M, Zettl H, Walter M, Rupp M, Reisen F, Proschak E, Weggen S, Stark H, Schneider G. DOGS: reaction-driven de novo design of bioactive compounds. Plos Computational Biology. 8: e1002380. PMID 22359493 DOI: 10.1371/journal.pcbi.1002380  1
2012 Pflanzner T, Petsch B, André-Dohmen B, Müller-Schiffmann A, Tschickardt S, Weggen S, Stitz L, Korth C, Pietrzik CU. Cellular prion protein participates in amyloid-β transcytosis across the blood-brain barrier. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 32: 628-32. PMID 22293988 DOI: 10.1038/jcbfm.2012.7  1
2012 Jumpertz T, Rennhack A, Ness J, Baches S, Pietrzik CU, Bulic B, Weggen S. Presenilin is the molecular target of acidic γ-secretase modulators in living cells. Plos One. 7: e30484. PMID 22238696 DOI: 10.1371/journal.pone.0030484  1
2012 Deng J, Hou H, Giunta B, Mori T, Wang YJ, Fernandez F, Weggen S, Araki W, Obregon D, Tan J. Autoreactive-Aβ antibodies promote APP β-secretase processing. Journal of Neurochemistry. 120: 732-40. PMID 22188568 DOI: 10.1111/j.1471-4159.2011.07629.x  1
2012 Isbert S, Wagner K, Eggert S, Schweitzer A, Multhaup G, Weggen S, Kins S, Pietrzik CU. APP dimer formation is initiated in the endoplasmic reticulum and differs between APP isoforms. Cellular and Molecular Life Sciences : Cmls. 69: 1353-75. PMID 22105709 DOI: 10.1007/s00018-011-0882-4  1
2012 Hillmann A, Hahn S, Schilling S, Hoffmann T, Demuth HU, Bulic B, Schneider-Axmann T, Bayer TA, Weggen S, Wirths O. No improvement after chronic ibuprofen treatment in the 5XFAD mouse model of Alzheimer's disease. Neurobiology of Aging. 33: 833.e39-50. PMID 21943956 DOI: 10.1016/j.neurobiolaging.2011.08.006  1
2011 Bulic B, Ness J, Hahn S, Rennhack A, Jumpertz T, Weggen S. Chemical Biology, Molecular Mechanism and Clinical Perspective of γ-Secretase Modulators in Alzheimer's Disease. Current Neuropharmacology. 9: 598-622. PMID 22798753 DOI: 10.2174/157015911798376352  1
2011 Hieke M, Ness J, Steri R, Greiner C, Werz O, Schubert-Zsilavecz M, Weggen S, Zettl H. SAR studies of acidic dual γ-secretase/PPARγ modulators. Bioorganic & Medicinal Chemistry. 19: 5372-82. PMID 21873070 DOI: 10.1016/j.bmc.2011.08.003  1
2011 Sagi SA, Lessard CB, Winden KD, Maruyama H, Koo JC, Weggen S, Kukar TL, Golde TE, Koo EH. Substrate sequence influences γ-secretase modulator activity, role of the transmembrane domain of the amyloid precursor protein. The Journal of Biological Chemistry. 286: 39794-803. PMID 21868380 DOI: 10.1074/jbc.M111.277228  1
2011 Jefferson T, ÄŒauÅ¡ević M, auf dem Keller U, Schilling O, Isbert S, Geyer R, Maier W, Tschickardt S, Jumpertz T, Weggen S, Bond JS, Overall CM, Pietrzik CU, Becker-Pauly C. Metalloprotease meprin beta generates nontoxic N-terminal amyloid precursor protein fragments in vivo. The Journal of Biological Chemistry. 286: 27741-50. PMID 21646356 DOI: 10.1074/jbc.M111.252718  1
2011 Heneka MT, Kummer MP, Weggen S, Bulic B, Multhaup G, Münter L, Hüll M, Pflanzner T, Pietrzik CU. Molecular mechanisms and therapeutic application of NSAIDs and derived compounds in Alzheimer's disease. Current Alzheimer Research. 8: 115-31. PMID 21345168  1
2011 Hahn S, Brüning T, Ness J, Czirr E, Baches S, Gijsen H, Korth C, Pietrzik CU, Bulic B, Weggen S. Presenilin-1 but not amyloid precursor protein mutations present in mouse models of Alzheimer's disease attenuate the response of cultured cells to γ-secretase modulators regardless of their potency and structure. Journal of Neurochemistry. 116: 385-95. PMID 21091478 DOI: 10.1111/j.1471-4159.2010.07118.x  1
2011 Pflanzner T, Janko MC, André-Dohmen B, Reuss S, Weggen S, Roebroek AJ, Kuhlmann CR, Pietrzik CU. LRP1 mediates bidirectional transcytosis of amyloid-β across the blood-brain barrier. Neurobiology of Aging. 32: 2323.e1-11. PMID 20630619 DOI: 10.1016/j.neurobiolaging.2010.05.025  1
2010 Richter L, Munter LM, Ness J, Hildebrand PW, Dasari M, Unterreitmeier S, Bulic B, Beyermann M, Gust R, Reif B, Weggen S, Langosch D, Multhaup G. Amyloid beta 42 peptide (Abeta42)-lowering compounds directly bind to Abeta and interfere with amyloid precursor protein (APP) transmembrane dimerization. Proceedings of the National Academy of Sciences of the United States of America. 107: 14597-602. PMID 20679249 DOI: 10.1073/pnas.1003026107  1
2010 Zettl H, Weggen S, Schneider P, Schneider G. Exploring the chemical space of gamma-secretase modulators. Trends in Pharmacological Sciences. 31: 402-10. PMID 20591508 DOI: 10.1016/  1
2010 Hieke M, Ness J, Steri R, Dittrich M, Greiner C, Werz O, Baumann K, Schubert-Zsilavecz M, Weggen S, Zettl H. Design, synthesis, and biological evaluation of a novel class of gamma-secretase modulators with PPARgamma activity. Journal of Medicinal Chemistry. 53: 4691-700. PMID 20503989 DOI: 10.1021/jm1003073  1
2010 Reekmans SM, Pflanzner T, Gordts PL, Isbert S, Zimmermann P, Annaert W, Weggen S, Roebroek AJ, Pietrzik CU. Inactivation of the proximal NPXY motif impairs early steps in LRP1 biosynthesis. Cellular and Molecular Life Sciences : Cmls. 67: 135-45. PMID 19856143 DOI: 10.1007/s00018-009-0171-7  1
2009 Jäger S, Leuchtenberger S, Martin A, Czirr E, Wesselowski J, Dieckmann M, Waldron E, Korth C, Koo EH, Heneka M, Weggen S, Pietrzik CU. alpha-secretase mediated conversion of the amyloid precursor protein derived membrane stub C99 to C83 limits Abeta generation. Journal of Neurochemistry. 111: 1369-82. PMID 19804379 DOI: 10.1111/j.1471-4159.2009.06420.x  1
2009 Kummer MP, Maruyama H, Huelsmann C, Baches S, Weggen S, Koo EH. Formation of Pmel17 amyloid is regulated by juxtamembrane metalloproteinase cleavage, and the resulting C-terminal fragment is a substrate for gamma-secretase. The Journal of Biological Chemistry. 284: 2296-306. PMID 19047044 DOI: 10.1074/jbc.M808904200  1
2009 Leuchtenberger S, Maler J, Czirr E, Ness J, Lichtenthaler SF, Esselmann H, Pietrzik CU, Wiltfang J, Weggen S. Nonsteroidal anti-inflammatory drugs and ectodomain shedding of the amyloid precursor protein. Neuro-Degenerative Diseases. 6: 1-8. PMID 18349521 DOI: 10.1159/000121391  1
2008 Waldron E, Heilig C, Schweitzer A, Nadella N, Jaeger S, Martin AM, Weggen S, Brix K, Pietrzik CU. LRP1 modulates APP trafficking along early compartments of the secretory pathway. Neurobiology of Disease. 31: 188-97. PMID 18559293 DOI: 10.1016/j.nbd.2008.04.006  1
2008 Waldron E, Isbert S, Kern A, Jaeger S, Martin AM, Hébert SS, Behl C, Weggen S, De Strooper B, Pietrzik CU. Increased AICD generation does not result in increased nuclear translocation or activation of target gene transcription. Experimental Cell Research. 314: 2419-33. PMID 18559276 DOI: 10.1016/j.yexcr.2008.05.003  1
2008 Czirr E, Cottrell BA, Leuchtenberger S, Kukar T, Ladd TB, Esselmann H, Paul S, Schubenel R, Torpey JW, Pietrzik CU, Golde TE, Wiltfang J, Baumann K, Koo EH, Weggen S. Independent generation of Abeta42 and Abeta38 peptide species by gamma-secretase. The Journal of Biological Chemistry. 283: 17049-54. PMID 18426795 DOI: 10.1074/jbc.M802912200  1
2008 Martin AM, Kuhlmann C, Trossbach S, Jaeger S, Waldron E, Roebroek A, Luhmann HJ, Laatsch A, Weggen S, Lessmann V, Pietrzik CU. The functional role of the second NPXY motif of the LRP1 beta-chain in tissue-type plasminogen activator-mediated activation of N-methyl-D-aspartate receptors. The Journal of Biological Chemistry. 283: 12004-13. PMID 18321860 DOI: 10.1074/jbc.M707607200  1
2008 Narlawar R, Pickhardt M, Leuchtenberger S, Baumann K, Krause S, Dyrks T, Weggen S, Mandelkow E, Schmidt B. Curcumin-derived pyrazoles and isoxazoles: Swiss army knives or blunt tools for Alzheimer's disease? Chemmedchem. 3: 165-72. PMID 17943713 DOI: 10.1002/cmdc.200700218  1
2007 Weggen S, Rogers M, Eriksen J. NSAIDs: small molecules for prevention of Alzheimer's disease or precursors for future drug development? Trends in Pharmacological Sciences. 28: 536-43. PMID 17900710 DOI: 10.1016/  0.44
2007 Czirr E, Leuchtenberger S, Dorner-Ciossek C, Schneider A, Jucker M, Koo EH, Pietrzik CU, Baumann K, Weggen S. Insensitivity to Abeta42-lowering nonsteroidal anti-inflammatory drugs and gamma-secretase inhibitors is common among aggressive presenilin-1 mutations. The Journal of Biological Chemistry. 282: 24504-13. PMID 17573346 DOI: 10.1074/jbc.M700618200  1
2007 Weggen S, Czirr E, Leuchtenberger S, Eriksen J. Nonsteroidal anti-inflammatory drugs (NSAIDs) and derived Aβ42-lowering molecules for treatment and prevention of Alzheimer's disease (AD) Pharmacological Mechanisms in Alzheimer's Therapeutics. 167-193. DOI: 10.1007/978-0-387-71522-3_11  1
2006 Leuchtenberger S, Beher D, Weggen S. Selective modulation of Abeta42 production in Alzheimer's disease: non-steroidal anti-inflammatory drugs and beyond. Current Pharmaceutical Design. 12: 4337-55. PMID 17105431 DOI: 10.2174/138161206778793029  1
2006 Czirr E, Weggen S. Gamma-secretase modulation with Abeta42-lowering nonsteroidal anti-inflammatory drugs and derived compounds. Neuro-Degenerative Diseases. 3: 298-304. PMID 17047371 DOI: 10.1159/000095270  1
2006 Leuchtenberger S, Kummer MP, Kukar T, Czirr E, Teusch N, Sagi SA, Berdeaux R, Pietrzik CU, Ladd TB, Golde TE, Koo EH, Weggen S. Inhibitors of Rho-kinase modulate amyloid-beta (Abeta) secretion but lack selectivity for Abeta42. Journal of Neurochemistry. 96: 355-65. PMID 16300630 DOI: 10.1111/j.1471-4159.2005.03553.x  1
2005 Kukar T, Murphy MP, Eriksen JL, Sagi SA, Weggen S, Smith TE, Ladd T, Khan MA, Kache R, Beard J, Dodson M, Merit S, Ozols VV, Anastasiadis PZ, Das P, et al. Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production. Nature Medicine. 11: 545-50. PMID 15834426 DOI: 10.1038/nm1235  1
2004 Pietrzik CU, Yoon IS, Jaeger S, Busse T, Weggen S, Koo EH. FE65 constitutes the functional link between the low-density lipoprotein receptor-related protein and the amyloid precursor protein. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 24: 4259-65. PMID 15115822 DOI: 10.1523/JNEUROSCI.5451-03.2004  1
2003 Waha A, Waha A, Koch A, Meyer-Puttlitz B, Weggen S, Sörensen N, Tonn JC, Albrecht S, Goodyer CG, Berthold F, Wiestler OD, Pietsch T. Epigenetic silencing of the HIC-1 gene in human medulloblastomas. Journal of Neuropathology and Experimental Neurology. 62: 1192-201. PMID 14656076  1
2003 Eriksen JL, Sagi SA, Smith TE, Weggen S, Das P, McLendon DC, Ozols VV, Jessing KW, Zavitz KH, Koo EH, Golde TE. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. The Journal of Clinical Investigation. 112: 440-9. PMID 12897211 DOI: 10.1172/JCI18162  1
2003 Weggen S, Eriksen JL, Sagi SA, Pietrzik CU, Ozols V, Fauq A, Golde TE, Koo EH. Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity. The Journal of Biological Chemistry. 278: 31831-7. PMID 12805356 DOI: 10.1074/jbc.M303592200  1
2003 Sagi SA, Weggen S, Eriksen J, Golde TE, Koo EH. The non-cyclooxygenase targets of non-steroidal anti-inflammatory drugs, lipoxygenases, peroxisome proliferator-activated receptor, inhibitor of kappa B kinase, and NF kappa B, do not reduce amyloid beta 42 production. The Journal of Biological Chemistry. 278: 31825-30. PMID 12805355 DOI: 10.1074/jbc.M303588200  1
2003 Carbone M, Bocchetta M, Cristaudo A, Emri S, Gazdar A, Jasani B, Lednicky J, Miele L, Mutti L, Pass HI, Ramael M, Rizzo P, Testa JR, Weggen S, Yeung A. SV40 and human brain tumors. International Journal of Cancer. Journal International Du Cancer. 106: 140-2; author reply . PMID 12794770 DOI: 10.1002/ijc.11189  1
2003 Weggen S, Eriksen JL, Sagi SA, Pietrzik CU, Golde TE, Koo EH. Abeta42-lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) and ErbB-4 receptor and signaling through the APP intracellular domain. The Journal of Biological Chemistry. 278: 30748-54. PMID 12777371 DOI: 10.1074/jbc.M304824200  1
2003 Wirths O, Waha A, Weggen S, Schirmacher P, Kühne T, Goodyer CG, Albrecht S, Von Schweinitz D, Pietsch T. Overexpression of human Dickkopf-1, an antagonist of wingless/WNT signaling, in human hepatoblastomas and Wilms' tumors. Laboratory Investigation; a Journal of Technical Methods and Pathology. 83: 429-34. PMID 12649343  1
2002 Pietrzik CU, Busse T, Merriam DE, Weggen S, Koo EH. The cytoplasmic domain of the LDL receptor-related protein regulates multiple steps in APP processing. The Embo Journal. 21: 5691-700. PMID 12411487 DOI: 10.1093/emboj/cdf568  1
2002 Golde TE, Eriksen JL, Weggen S, Sagi SA, Koo EH. Nonsteroidal antiinflammatory drugs as therapeutic agents for Alzheimer's disease Drug Development Research. 56: 415-420. DOI: 10.1002/ddr.10093  1
2001 Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, Kang DE, Marquez-Sterling N, Golde TE, Koo EH. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature. 414: 212-6. PMID 11700559 DOI: 10.1038/35102591  1
2001 Weggen S, Preuss U, Pietsch T, Hilger N, Klawitz I, Scheidtmann KH, Wiestler OD, Bayer TA. Identification of amplified genes from SV40 large T antigen-induced rat PNET cell lines by subtractive cDNA analysis and radiation hybrid mapping. Oncogene. 20: 2023-31. PMID 11360186 DOI: 10.1038/sj.onc.1204287  1
2000 Weggen S, Bayer TA, von Deimling A, Reifenberger G, von Schweinitz D, Wiestler OD, Pietsch T. Low frequency of SV40, JC and BK polyomavirus sequences in human medulloblastomas, meningiomas and ependymomas. Brain Pathology (Zurich, Switzerland). 10: 85-92. PMID 10668898  1
1999 Kappler R, Pietsch T, Weggen S, Wiestler OD, Scherthan H. Chromosomal imbalances and DNA amplifications in SV40 large T antigen-induced primitive neuroectodermal tumor cell lines of the rat. Carcinogenesis. 20: 1433-8. PMID 10426788 DOI: 10.1093/carcin/20.8.1433  1
1999 Bayer TA, Thier M, Roeb E, Breuer B, Weggen S, Wiestler OD, Weis J. Migratory potential of transplantable neural tumor cell lines. Acta Neuropathologica. 97: 607-12. PMID 10378379 DOI: 10.1007/s004010051036  1
1999 Diehlmann A, Ida N, Weggen S, Grünberg J, Haass C, Masters CL, Bayer TA, Beyreuther K. Analysis of presenilin 1 and presenilin 2 expression and processing by newly developed monoclonal antibodies. Journal of Neuroscience Research. 56: 405-19. PMID 10340748 DOI: 10.1002/(SICI)1097-4547(19990515)56:4<405::AID-JNR8>3.0.CO;2-F  1
1999 Salewski H, Bayer TA, Eidhoff U, Preuss U, Weggen S, Scheidtmann KH. Increased oncogenicity of subclones of SV40 large T-induced neuroectodermal tumor cell lines after loss of large T expression and concomitant mutation in p53. Cancer Research. 59: 1980-6. PMID 10213510  1
1999 Egensperger R, Weggen S, Ida N, Multhaup G, Schnabel R, Beyreuther K, Bayer TA. Reverse relationship between beta-amyloid precursor protein and beta-amyloid peptide plaques in Down's syndrome versus sporadic/familial Alzheimer's disease. Acta Neuropathologica. 97: 113-8. PMID 9928821 DOI: 10.1007/s004010050963  1
1999 Weggen S, Tienari PJ, Beyreuther K, Bayer TA. Retroviral shuttle vectors in Alzheimer's disease research Neurology Psychiatry and Brain Research. 6: 213-218.  1
1998 Weggen S, Diehlmann A, Buslei R, Beyreuther K, Bayer TA. Prominent expression of presenilin-1 in senile plaques and reactive astrocytes in Alzheimer's disease brain. Neuroreport. 9: 3279-83. PMID 9831464  1
1997 Bayer TA, Paliga K, Weggen S, Wiestler OD, Beyreuther K, Multhaup G. Amyloid precursor-like protein 1 accumulates in neuritic plaques in Alzheimer's disease. Acta Neuropathologica. 94: 519-24. PMID 9444352 DOI: 10.1007/s004010050745  1
1997 Weggen S, Bayer TA, Koch A, Salewski H, Scheidtmann KH, Pietsch T, Wiestler OD. Characterization of neural cell lines derived from SV40 large T-induced primitive neuroectodermal tumors. Brain Pathology (Zurich, Switzerland). 7: 731-9. PMID 9161724  1
1997 Bayer TA, Weggen S, Hesse L, Cappai R, Masters CL, Beyreuther K, Multhaup G. Distribution of amyloid precursor-like protein 2 in normal and Alzheimer's disease hippocampal formation Alzheimer's Research. 3: 199-203.  1
Show low-probability matches.